Trial reportPsychopharmacology2015
New onset executive function difficulties at menopause: a possible role for lisdexamfetamine.
Trial report in Psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Attention & Memory Impairments in Menopausal Women: A Possible Role for Vyvanse?
Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women
Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- ADHD and Sex Hormones in Females: A Systematic Review.Journal of attention disorders · 2025Pooled it
- Pooled it
- Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.Gynecologic oncology · 2024Trial
- The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study.Translational psychiatry · 2022Trial
- Impact of Tryptophan Depletion on Executive System Function during Menopause is Moderated by Childhood Adversity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Impact of early life adversity and tryptophan depletion on functional connectivity in menopausal women: A double-blind, placebo-controlled crossover study.Psychoneuroendocrinology · 2017Trial
- ADHD and the female reproductive stages: menstruation, perinatal and menopause.Archives of women's mental health · 2026Article
- Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause.Drugs & aging · 2026Review
- Examining the Link Between ADHD Symptoms and Menopausal Experiences.Journal of attention disorders · 2025Article
- Incarcerated adolescents scoring high on the Brown Attention-Deficit Disorder Scale are characterized by impairments within brain regions associated with executive control: A source-based morphometry study.Psychiatry research. Neuroimaging · 2025Article
- What a boy wants: Transgender men's hidden tran/scripts about the nonprescription use of gender-affirming hormones in mainland China.Social science & medicine (1982) · 2025Article
- Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease.Frontiers in global women's health · 2025Review
- Hormones as Psychotropic Interventions in Females.Focus (American Psychiatric Publishing) · 2024Article
- Cognitive Problems in Perimenopause: A Review of Recent Evidence.Current psychiatry reports · 2023Review
- Article
- Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study.The journal of prevention of Alzheimer's disease · 2023Article
- ADHD Symptoms in Females of Childhood, Adolescent, Reproductive and Menopause Period.Materia socio-medica · 2021Review
- Neuropsychiatric effects of tamoxifen: Challenges and opportunities.Frontiers in neuroendocrinology · 2020Review
- Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?Menopause (New York, N.Y.) · 2020Article
- What has sex got to do with it? The role of hormones in the transgender brain.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
rationaleReports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women.
objectiveThis study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints.
methodsThirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40-60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest.
resultsAnalyses revealed a significant effect of LDX treatment over placebo for total BADDS scores (p = 0.0001) and for four out of the five BADDS subscales (all p < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall (p = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure (p = 0.017) and heart rate increased significantly (p = 0.006) when women were on LDX but remained, on average, within the normal range.
conclusionsLDX 40-60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.